TechConnect Innovation Program

High Performance Nanoparticle-Based MRI Contrast Agent

Theragnostic Technologies Inc, NY, United States

TECHNOLOGY SUMMARY

We have developed a novel nanoparticle-based MRI contrast agent that shows efficacy an order of magnitude higher than current clinical MRI contrast agents, and is safe for use in patients with kidney problems for whom current clinical MRI contrast agents are restricted for use.

Primary Application Area: Biotech & Biological Sciences

Technology Development Status: Prototype

Technology Readiness Level: TRL 3

FIGURES OF MERIT

Value Proposition: This technology, upon complete development, will be the first FDA-approved MRI CA specifically for diagnosis and monitoring of renal failure, thereby overcoming the significant limitation of currently available clinical CT and MRI CAs.

SHOWCASE SUMMARY

Organization Type: Early-stage Startup (Seed)

Showcase Booth #: 23M - 58T

Website: www.theragnostictechnologies.com

GOVT/EXTERNAL FUNDING SOURCES

Government Funding/Support to Date: STTR Phase 1 - National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, $150,000, 2013-2014 (1 year)
SBIR Phase 2 - National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, $1,400,000, 2015-2017 (2 years)
Technology Accelerator Fund, Research Foundation, State University of New York, $50,000, 2014-15 (6 months)

Primary Sources of Funding: Angel, Friends, Family, Personal Savings, Federal Grant, University, Other

Looking for: Both Funding and Development Partners